Pharmascience Inc is proud to announce that it has acquired Uman Pharma Inc. on November 13, 2014.
May 1, 2008 - Uman Pharma is proud to announce the acquisition of the Bristol Myers-Squibb facility in Candiac (Canada).
Uman Pharma is proud to announce the acquisition of the Bristol Myers-Squibb facility in Candiac (Canada).
Montreal, May 1st, 2009 UMAN PHARMA Inc., a new Quebec company specializing in the manufacturing (CMO) and the distribution of oncology products, is proud to announce the acquisition of the Bristol Myers Squibb facility in Candiac (Canada). The 130 000 sq ft plant holds two manufacturing units: one for oncology products and another for solid dosage formulations, as well as twenty laboratories fully equipped to provide research and development, product formulation and quality control. This state-of-the-art facility has great capacity and meets the highest standards in pharmaceutical manufacturing: cGMP, FDA (USA), TPD (Canada) and EMEA (Europe). UMAN PHARMA will offer a wide range of services, from developmental to scale-up to manufacturing of clinical lots, manufacturing of commercial lots (tablets, capsules, oncology and sterile products), lyophilization, as well as providing, to proprietary and generic pharmaceutical companies, the research and the product development support they need at the clinical or at the commercial stage. The Bristol Myers Squibb facility in Candiac is recognized worldwide for its Research & Development expertise and manufacturing achievements. Key ex-employees of Bristol Myers Squibb, who contributed to this reputation, have been hired by UMAN PHARMA. UMAN PHARMA is a privately owned company, held and managed by a group of executives who are well-established and experienced in the pharmaceutical industry, as well as private investors and Carrefour-Capital LLP Fund. FOR FURTHER INFORMATION, PLEASE CONTACT: Sylvain Duvernay Chief Executive Officer (450) 444-9989, ext. 5000